Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Alice M Jackson
  • Mark C Petrie
  • Alexandra Frogoudaki
  • Cécile Laroche
  • Finn Gustafsson
  • Bassem Ibrahim
  • Alexandre Mebazaa
  • Mark R Johnson
  • Petar M Seferovic
  • Vera Regitz-Zagrosek
  • Amam Mbakwem
  • Michael Böhm
  • Hawani S Prameswari
  • Doaa A Fouad
  • Sorel Goland
  • Albertino Damasceno
  • Kamilu Karaye
  • Hasan A Farhan
  • Righab Hamdan
  • Aldo P Maggioni
  • Karen Sliwa
  • Johann Bauersachs
  • Peter van der Meer
  • PPCM Investigators Group
Vis graf over relationer

AIMS: Hypertensive disorders occur in women with peripartum cardiomyopathy (PPCM). How often hypertensive disorders co-exist, and to what extent they impact outcomes, is less clear. We describe differences in phenotype and outcomes in women with PPCM with and without hypertensive disorders during pregnancy.

METHODS AND RESULTS: The European Society of Cardiology EURObservational Research Programme PPCM Registry enrolled women with PPCM from 2012-2018. Three groups were examined: (i) women without hypertension (PPCM-noHTN); (ii) women with hypertension but without pre-eclampsia (PPCM-HTN); (iii) women with pre-eclampsia (PPCM-PE). Maternal (6-month) and neonatal outcomes were compared. Of 735 women included, 452 (61.5%) had PPCM-noHTN, 99 (13.5%) had PPCM-HTN and 184 (25.0%) had PPCM-PE. Compared to women with PPCM-noHTN, women with PPCM-PE had more severe symptoms (New York Heart Association class IV in 44.4% vs. 29.9%, P < 0.001), more frequent signs of heart failure (pulmonary rales in 70.7% vs. 55.4%, P = 0.002), a higher baseline left ventricular ejection fraction (LVEF) (32.7% vs. 30.7%, P = 0.005) and a smaller left ventricular end-diastolic diameter (57.4 ± 6.7 mm vs. 59.8 ± 8.1 mm, P = 0.001). There were no differences in the frequencies of death from any cause, rehospitalization for any cause, stroke, or thromboembolic events. Compared to women with PPCM-noHTN, women with PPCM-PE had a greater likelihood of left ventricular recovery (LVEF ≥ 50%) (adjusted odds ratio 2.08, 95% confidence interval 1.21-3.57) and an adverse neonatal outcome (composite of termination, miscarriage, low birth weight or neonatal death) (adjusted odds ratio 2.84, 95% confidence interval 1.66-4.87).

CONCLUSION: Differences exist in phenotype, recovery of cardiac function and neonatal outcomes according to hypertensive status in women with PPCM.

TidsskriftEuropean Journal of Heart Failure
Sider (fra-til)epub
StatusE-pub ahead of print - 11 jun. 2021

Bibliografisk note

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

ID: 68255169